Related Experiment Video
Updated: Sep 19, 2025
09:14
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
Published on: September 28, 2022
4.1K
The PD-1/PD-L1 pathway and Epstein-Barr virus
Hui Wang1, Ning Zhang1, Rongshuang Xu1
1Department of Pediatrics, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, China.
European Journal of Medical Research
|June 18, 2025
Summary
The PD-1/PD-L1 pathway plays a complex role in Epstein-Barr virus (EBV) infection, impacting immune evasion and T cell function during infectious mononucleosis (IM). Understanding this pathway is crucial for diagnosing EBV progression and developing new therapies.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Epstein-Barr virus (EBV), a gamma-herpesvirus, establishes latent infections in lymphocytes and can lead to lymphoproliferative disorders.
- The PD-1/PD-L1 immune checkpoint pathway is implicated in chronic viral infections, but its specific role in EBV pathogenesis is not fully understood.
- PD-1 upregulation on Epstein-Barr virus-specific CD8+ T cells during acute infectious mononucleosis (IM) and its effect on T cell function remain unclear.
Purpose of the Study:
- To systematically review the current knowledge on PD-1/PD-L1 signaling in EBV infection.
- To analyze the dual role of the PD-1/PD-L1 pathway in immune homeostasis and viral persistence during acute EBV infection.
- To explore the potential of PD-1/PD-L1 as a biomarker for disease progression and therapeutic target in EBV-associated conditions.
Main Methods:
- Systematic literature review and critical analysis of existing research on PD-1/PD-L1 signaling in EBV infection.
- Evaluation of studies investigating the impact of PD-1/PD-L1 pathway on T cell function and immune evasion during EBV infection.
- Assessment of the diagnostic and prognostic potential of PD-1/PD-L1 as biomarkers in EBV-related diseases, particularly IM.
Main Results:
- The PD-1/PD-L1 pathway exhibits a dual role, potentially aiding immune evasion by EBV while also being involved in immune regulation during acute infection.
- Evidence suggests PD-1/PD-L1 pathway modulation may serve as a diagnostic biomarker for disease progression in infectious mononucleosis.
- The pathway's role in cytotoxic T cell function and immune regulation during EBV infection is complex and requires further elucidation.
Conclusions:
- The PD-1/PD-L1 pathway is a critical factor in the interplay between EBV and the host immune system, influencing viral persistence and immune evasion.
- Further research is needed to fully understand the PD-1/PD-L1 pathway's implications for EBV pathogenesis, diagnosis, and prognosis.
- Targeting the PD-1/PD-L1 pathway holds therapeutic potential for optimizing EBV-specific immunotherapies and managing EBV-associated malignancies.
